


































Aging is a multi-factorial process affecting every organ 
of the body.  In the past, aging research has primarily 
focused on neurodegeneration and loss of bone mass.   
Not much attention has been given to sarcopenia until 
recently.  Sarcopenia refers to the physiological loss of 
skeletal muscle mass and function during aging [1]. 
Several age-related changes occur in skeletal muscle 
including a decrease in myofiber size and number and a 
diminished ability of satellite cells to activate and 
proliferate upon injury leading to impaired muscle 
remodeling [2, 3].  The progressive loss of muscle mass 
poses health risks for older adults that lead to a decrease 
in physical activity and a rise in the incidence of falls and 
related fractures.  Rehabilitation time is often prolonged 
after injury, which in turn extends the duration of bed 
rest resulting in disuse atrophy, an additional variable 
that is exaggerated in the aging population [4-6] thus 
interfering with a successful recovery.  
 
 

































Sarcopenia is a major public health problem affecting 
approximately 25% of people under the age of 70 and 
40% of people age 80 years and older [7].  In 2000, 
sarcopenia-related healthcare expenses totaled 
approximately $18.5 billion in the United States [8]. 
However, the projected aging-related expenses are 
expected to exponentially increase because older people 
are the fastest growing population in the US [9] with the 
number of individuals over 60 years of age doubling 
over the next 40 years [10].   
 
Considering the impact of sarcopenia on the well-being 
of older adults and the healthcare system in general, it is 
critical to identify widespread therapeutic strategies to 
maintain skeletal muscle homeostasis and repair.  While 
strength and aerobic exercise have been documented to 
attenuate [11] and even reverse sarcopenia [12, 13], a 
recent study reported only 2% of older subjects 
exercised on a regular basis [14].  Therefore, there is a 






























strategies.    
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interplay of biological and environmental factors would 
be a preferred because they both contribute to the 
vicious cycle that drives sarcopenia.  Recent studies 
have highlighted caloric restriction (CR) and caloric 
restriction mimetics (CRM) as potential mechanisms to 
combat aging and sarcopenia.  This article summarizes 
the current knowledge about the effects of these 




The molecular mechanisms underlying sarcopenia are 
not fully elucidated.  However several lines of evidence 
have connected many different age-related changes to 
the resulting decrease in muscle mass and function: 
increases in apoptosis and reactive oxidative species 
(ROS); decreases in autophagy; modulation of signaling 
pathways involved in skeletal muscle homeostasis and 
excitation-contraction (EC) uncoupling.  All of these 
factors appear to contribute to the progression of 
sarcopenia albeit no single factor can independently 
account for the aging-related changes occurring in 
skeletal muscle. 
 
Factors Impacting Skeletal Muscle Structure 
Histologically, the age-related loss of muscle mass is 
characterized by a decrease in muscle fiber size and 
number with a preferentially loss of type II fibers [15, 
16]. Due to the impaired ability of skeletal muscle to 
remodel, the loss of myofibers can be accompanied by 
the infiltration of adipose tissue, inflammation and/or 
fibrotic tissue [17-21]. Other markers of impaired 
remodeling such as variation of fiber size, increase in 
centralized nuclei and an increase in atrophic, angulated 
fibers are often present [22].   Proposed mechanisms for 
the loss of muscle size and number including increased 
ROS, mitochondrial DNA (mtDNA) mutations, 
impaired autophagy and increased apoptosis appear to 
function synergistically to contribute to the 
pathogenesis of sarcopenia. 
 
A progressive decline in mitochondria function leads to 
an increase in the formation of oxidative stress and ROS 
production.  The increase in ROS leads to mtDNA 
deletions and mutations, macromolecular oxidation, 
electron transport chain (ETC) dysfunction, cellular 
senescence and cell death [23-25].  Oxidative damage to 
proteins may alter their structure and function leading to 
the formation of aggregates. Oxidized proteins may be 
ubiquitinated in order to be targeted by the proteosome 
for degradation. However during aging of skeletal 
muscle, there is an increase in the accumulation of 
oxidized proteins, attributed to a decline in the activity 
of the proteosome [26].  Conversely, recent data report 
an increase in the number of proteosomes with normal 
degradative capacity, suggesting enhanced proteosome 
activity contributes to muscle loss [27].  Therefore, the 
role of the ubiquitin-proteosome activity in sarcopenia 
requires further clarification.  Nonetheless under normal 
physiological conditions, the cell undergoes autophagy 
to protect itself from accumulation of protein 
aggregates, but there is a decline in the activity and 
efficiency of autophagy with age. Consequently there is 
an intracellular accumulation of protein aggregates, 
impaired autophagy [28], increased apoptosis and 
oxidative stress [28] associated with impaired energy 
production due to damaged mitochondria [28-30]. 
 
With age, alterations in the expression of autophagy-
related genes have been reported.  Studies have shown 
an increase in Beclin-1 and a decrease in LC3, LAMP-
2, Bnip-3 and Gabarap1 [28, 31].  These changes lead to 
impaired autophagy with a decline in its degradation 
activity causing post-mitotic cells to accumulate 
biological garbage.  Furthermore, the process of 
autophagy is necessary to maintain skeletal muscle 
mass.  Skeletal muscle specific inhibition of autophagy 
using mice deficient in Atg7 has resulted in a phenotype 
similar to sarcopenia: muscle atrophy, loss of force, 
accumulation of abnormal mitochondria, protein 
aggregates, oxidative stress and apoptosis [32, 33]. 
 
Accelerated apoptosis, as seen in aging, likely also 
contributes to the loss of myofibers observed in 
sarcopenia.  Apoptosis could be a consequence of the 
impaired autophagy and abnormal mitochondria. 
Studies show an increase in mRNA, protein and/or 
activity levels of many pro-apoptotic markers including 
the BCL-2 family, caspases, Apaf-1, XIAP and 
cytochrome c [34, 35].  These increases are 
accompanied by an increase in apoptotic DNA 
fragmentation [28, 34] and a compensatory up-
regulation of anti-apoptotic factors [35-37]. Due to the 
multinucleated nature of skeletal muscle, it can undergo 
individual myonuclear apoptosis or complete cell death.  
The phenomenon of myonuclear apoptosis supports the 
nuclear domain hypothesis that states a single nucleus 
controls a defined cytoplasmic area.  Under this 
hypothesis, the removal of myonuclei is necessary for 
muscle atrophy to occur [6, 38].  
 
Age-related changes also occur in a number of critical 
signaling pathways that further promote the process of 
aging.  Although there are several signaling pathways 
linked to sarcopenia, we focus our discussion on the 
canonical and non-canonical transforming growth 
factor-β (TGF-β) cascade, Wnt signaling and the 
insulin-like growth factor-1 (IGF-1)/Akt/mammalian 
target of rapamycin (mTOR) pathways. 
   





































Loss of muscle mass in sarcopenia has been linked to 
the modulation of the canonical (Smad-dependent) and 
non-canonical (Smad-independent) TGF-β signaling 
cascades [3]. An increase in circulating TGF-β1 and 
phosphorylated Smad3 levels contribute to the 
formation of connective tissue within the extracellular 
matrix (ECM).  This interferes with the satellite cell 
niche, creating an environment that inhibits satellite cell 
activation and proliferation [3, 39], impairs myocyte 
differentiation [39, 40] and leads to the formation of 
fibrotic tissue in response to skeletal muscle injury [41].  
There are conflicting data concerning the activation of 
the non-canonical TGF-β mitogen-activated protein 
kinase (MAPK) pathway; it has been reported to be up-
regulated, down-regulated and unchanged in aged 
skeletal muscle [5, 42, 43].  Furthermore, MAPK has 
been shown to participate in a variety of functions includ-






































Although the exact role and concentrations of MAPK 
signaling in sarcopenia requires more research, it has 
been associated with creating a ‘stress-like’ condition in 
which aged muscle is constantly exposed when up-
regulated [42] and contributing to the impaired 
regeneration [5]. 
 
Wnt signaling has been shown to be involved in satellite 
cell proliferation and differentiation in skeletal muscle 
regeneration [44, 45].  It has been suggested that a 
temporal switch from notch to Wnt signaling occurs 
during the onset of differentiation[44], suggesting that 
timing and tissue homeostasis of these signaling 
pathways are important for efficient regeneration.  
Therefore impaired regeneration in aged skeletal muscle 
could be associated with an aging-related increase in the 
activation of Wnt signaling, evident by increased levels 
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and satellite cells and myogenic progenitor cells upon 
injury [44, 46].  Furthermore, the sustained activation of 
Wnt signaling in skeletal muscle is associated with stem 
cell aging and the transformation of myogenic to 
fibrotic tissue [46]. 
 
IGF-1 is a growth factor whose activation is critical in 
mediating the growth of skeletal muscle and its levels 
decrease with age [47].  Several lines of evidence have 
shown that the local administration of IGF-1 directly 
into skeletal muscle prevents the age-related loss of 
muscle mass [48], function [47] and regeneration [48]. 
Akt is a downstream effector of the IGF-1 pathway.   
Akt can induce protein synthesis through the 
phosphorylation and activation of mTOR and inhibit 
protein degradation through the phosphorylation and 
inactivation of FoxO3a. mTOR signaling is critical for 
muscle homeostasis, all stages of regeneration [49-51] 
and muscle hypertrophy [52-54].  FoxO3a signaling 
induces the transcriptional activation of atrogenes and 
autophagy-related genes resulting in protein 
degradation. Interestingly, there are discrepancies in the 
expression levels of atrogenes, MuRF-1 and atrogin-1, 
in sarcopenia [31, 55, 56]; although they have been 
linked with acute conditions of muscle atrophy [56, 57]. 
Thus, this pathway likely does not play a primary role 
in sarcopenia because its modulation depends on sex, 
age and muscle fiber type [58].  However, it is well 
documented that the loss of muscle mass during disuse 
as the result of inactivity and bed rest in young and aged 
skeletal muscle is associated with a reduction in the 
Akt/mTOR pathway [59-61].  Notably, sarcopenic 
muscle lacks the ability to sufficiently recover from 
disuse-induced atrophy as compared to young muscle 
[62]. Taken together, the existing data suggest that the 
IGF-1/Akt/mTOR pathway does not play a primary role 
in the process of sarcopenia, and that other regulators 
will need to be identified as possible modulators of 
sarcopenia. 
 
Factors Impacting Skeletal Muscle Function 
As a consequence to the loss of skeletal muscle mass, 
there is a 20-40% decline in muscle function [63].  This 
decline in function has been linked to several factors 
including the loss of muscle mass, apoptosis and 
impaired energy production due to damaged 
mitochondria as discussed above.  However, none of 
those factors have sufficiently accounted for the decline 
in muscle function.  Evidence has shown that the Ca
2+ 
dependent EC coupling process is impaired with age 
and contributes to the decline in function [64].  
 
Studies have shown that there is a decrease in the 
number of dihydropyridine receptors (DHPR) resulting 
in an increase in the amount of DHPR-unlinked 
ryanodine receptors (RyR1) during aging.  Therefore 
EC uncoupling occurs and results in impairment of the 
voltage-gated SR Ca
2+ release mechanism and a decline 
in contraction force [65].   Furthermore, the increase in 
oxidative stress causes nitrosylation and oxidation of 
the RyR1 complex.  The defective RyR1 complex 
causes an intracellular Ca
2+ leak that further disrupts 
mitochondria structure and function [66].  EC 
uncoupling and leaky RyR1 likely contribute to the loss 
of muscle function in sarcopenia. 
 
Environmental (lifestyle) Factors 
 
Nutrition 
Preservation of skeletal muscle mass is achieved by 
maintaining a homeostatic balance between protein 
synthesis and degradation [67]. During aging there is 
impaired protein metabolism associated with a decline 
in total food intake (anorexia of aging) [68].  This leads 
to deprivation of amino acids which blocks protein 
synthesis in older individuals. Furthermore, the anorexia 
of aging may lead to malnutrition, which is linked to 
modulation of different hormones including 
testosterone, leptin, growth hormone, and IGF-1 that 
contribute to muscle wasting [69]. 
 
Activity 
The decrease in muscle mass and strength has 
significant functional consequences for the elderly 
population.  Functional impairment defined as difficulty 
in mobility performance including walking, stooping 
and standing up from a chair and physical disability 
defined as difficulty with performing daily activities 
such as chores and cooking occurs 2 times and 3 times 
more likely in men and women, respectively, with 
sarcopenia when compared to those considered to have 
normal skeletal muscle index [14].   
 
The decline in physical activity increases susceptibility 
to disuse atrophy, a frequent problem for individuals of 
all ages, but a particularly challenging one for older 
adults.  When skeletal muscle is subjected to disuse for 
a prolonged period of time (i.e. bed rest), muscle 
atrophy occurs [1].  This atrophic response is a 
completely reversible process in the younger population 
[1]; however as a result of the physiological process of 
aging, humans are known to exhibit an exaggerated 
atrophy in response to disuse and an inability to rebuild 
muscle mass after immobilization [62, 70].  Studies 
performed in human subjects reported a 30% loss of 
skeletal muscle mass after only two weeks of 
immobilization in older men as compared to a loss of 
less than 2% in young men, and only 2.5% of the loss 
muscle repopulated [5].   Research has shown that 
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muscle cells as opposed to smaller cells observed in 
young muscle [60, 71]. 
 
Injury 
Advanced age, muscle weakness, lack of physical 
activity and functional limitations are risk factors that 
increase the incidence of falls and related fractures in 
older persons.  Twenty to thirty percent of elderly 
people who fall sustain injuries that further reduce 
mobility and independence, thereby increasing the 
sedentary lifestyle and bed rest [9].  Furthermore, the 
damage to the skeletal muscle upon fractures and the 
impaired regeneration due to modulation of signaling 
pathways leads to the replacement of skeletal muscle 
with connective tissue and a further decline in function 
and activity [60]. 
 
 
Therapeutic Interventions: Aging-focused 
 
The pathogenic etiology of sarcopenia is complex, 
characterized by the contribution of multiple factors 
[72]. It is reasonable to hypothesize that both biological 
and environmental factors contribute to its progression 
(Figure 1).  Due to its multi-factorial nature, researchers 
have taken different avenues to modulate phenotypes to 
combat sarcopenia.  Recent advances in anti-aging 
regimens have generated interest in the ability of these 
strategies to slow the progression of sarcopenia.   
Despite the complexity of aging and sarcopenia, it has 
been hypothesized that the anti-aging regimens should 
also benefit sarcopenia. 
 
Caloric Restriction 
One intervention that has been shown to attenuate 
sarcopenia is CR, the reduction in caloric intake without 
malnutrition [73].  The effects of CR on sarcopenia 
have been extensively studied using different model 
organisms, skeletal muscle groups and various dietary 
restrictions [30, 74-76].   It slowed down the 
progression of sarcopenia by decreasing the amount of 
myofiber atrophy and loss [75-78]. It also maintained 
the specific force and size of type II fibers [21].   
Furthermore, it attenuated skeletal muscle remodeling 
associated with sarcopenia by decreasing the amount of 
fibrotic tissue, variation in fiber size, centralized nuclei 
and angulated fibers [21, 22].  This phenotype was 
achieved through the modulation of different biological 
factors associated with sarcopenia. 
 
 The reduction of caloric intake alleviated the burden of 
ROS-related consequences by reducing  oxidative 
damage sustained to the mitochondrial proteins and 
lipids, the generation of superoxide anions [79], and the 
accumulation of deleted mitochondrial genomes and 
mitochondrial enzyme abnormities with age [75]. It also 
prevented the decline in autophagy by increasing the 
expression of Atg proteins and LC3 and LAMP2 genes 
[28].   The trypsin-like proteosome activity was sustain-
ed but did not result in a decrease of protein aggregates 
[26]. Furthermore, the increase in apoptosis was 
attenuated by a reduction in the levels of intrinsic and 
extrinsic apoptotic signals including the caspases, XIAP 
and AIF [35, 36, 80]. CR also prevented the age-related 
decline in muscle function [81] by maintaining the ratio 
of DHPR and RyR1 and preventing uncoupling [82].   
 
CR has been proven to correct multiple detrimental 
effects of aging on skeletal muscle as well as other age-
related diseases and longevity. However, implementing 
CR as a valuable therapeutic avenue for sarcopenia and 
aging consists of numerous problems [83].  One 
particular problem is determining the exact time frame 
for starting CR.  When started too early in life, it may 
cause developmental problems and if started too late, 
benefits may not be achieved [84].  Furthermore, CR, 
started late in life could contribute to the anorexia of 
aging and mortality [85].  Nonetheless the benefits of 
CR on aging and sarcopenia have lead to the search for 
CRMs. 
 
Caloric Restriction Mimetics 
CRMs are compounds that allow individuals to eat ad 
libitum while benefitting from the effects of CR.   
Ingram et al. proposes that potential CRM should meet 
the following criteria: (i) it mimics the metabolic, 
hormonal, and physiological effects of CR; (ii) it does 
not significantly reduce long-term food intake; (iii) it 
activates stress response pathways observed in CR and 
provides protection against a variety of stressors; and 
(iv) it produces CR-like effects on longevity, reduction 
of age-related disease and maintenance of function [86]. 
 
There are four main pathways that are the target for the 
development of CRMs: insulin/insulin-like growth 
factor 1 (IGF-1), sirtuin 1 (SIRT1), target of rapamycin 
(TOR), and 5’ adenosine monophosphate-activated 
protein kinase (AMPK) [87].  The majority of these 
pathways have been shown to extend lifespan and 
health span through pharmacological and genetic 
manipulation cite [88-91].  Common compounds used 
to manipulate these pathways include metformin, 
resveratrol and rapamycin. 
 
Metformin is a biguanide drug used to treat type-2 
diabetes, but the primary mechanism of hypoglycemic 
action is unknown [92].  However, it has been shown to 
inhibit the complex 1 of respiratory chain complex of 
the mitochondria as well as causing an increase in 
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Evidence has shown that metformin does not cause 
glucose uptake in skeletal muscle in non-diabetics [94, 
95].  Despite the conflicting information on the ability 
of metformin to extend lifespan [96, 97], it is a 
candidate CRM.  It is proposed to affect the AMPK, 
sirtuins, and TOR pathways [98]. Whether metformin is 
a valuable target for sarcopenia is questionable.  In 
particular, its inhibitory effect of the mTORC1 
signaling [99] may interfere with myogenesis and 
maintenance of muscle mass.  
 
Resveratrol is a small polyphenol in fruits and red wines 
at low concentrations[100].  It has been suggested to 
exhibit antioxidant and cardioprotective properties 
[100]. It has been identified as a CRM due to its 
potential ability to increase SIRT1 protein levels [101].  
However, reports have shown that it may not directly 
up-regulate SIRT [102] and that its exact molecular 
mechanism is unknown.   Resveratrol is known to 
activate and inhibit many different enzymes including 
AMPK [103], which is another pharmacological target 
for CR [104, 105]. Given the ability of resveratrol to 
either directly or indirectly affect sirtuins, AMPK and 
autophagy [103, 106, 107], it seems like a promising 
candidate to treat sarcopenia.  Moreover, resveratrol 
was shown to be protective against oxidative stress 
associated with loading, unloading and aging in skeletal 
muscle [106, 108].  However, it did not attenuate the 
age-related decline in muscle mass or function 
associated with sarcopenia in rodents over a prolonged 
period of time.   Furthermore, resveratrol did not affect 
the levels of SIRT1, PGC-1α, or cytochrome C in aged 
skeletal muscle [109].   
 
Rapamycin, an immunosuppressant that may have 
adverse effects in healthy individuals [110], inhibits 
TOR signaling [88].  Increased mammalian TOR 
(mTOR) signaling is a hallmark of the aging phenotype 
and mTOR-centric views of aging have recently 
emerged [111].  Studies have shown that inhibition of 
mTOR signaling is associated with ameliorating several 
age-related phenotypes including decelerating cellular 
senescence, altered translational control, increased 
mitochondria number and cellular respiration [112-114].  
Moreover, researchers have shown that mTOR may 
actually promote autophagy in a TORC Autophagy 
Secretory Colocalization Compartment (TASCC) in 
senescence cells as opposed to inhibiting autophagy 
outside out of the TASCC [115].   This has lead to the 
hypothesis that TOR signaling is alternatively regulated 
during aging. Indeed, it is known that TOR signaling 
has tissue-specific functions in mammals (71).   Perhaps 
systemically inhibiting TOR may prove problematic to 
cellular functions including secretory protein autophagy 
and to organs including skeletal muscle [110].  With age 
in humans, there is a decrease in TOR signaling in 
muscle [52] that may be linked to the progression of 
sarcopenia because TOR signaling is important in 
skeletal muscle homeostasis, all the stages of 
regeneration [49-51] and muscle hypertrophy [52-54].  
Therefore, systemically treating organisms with 
rapamycin may impair the muscles’ ability to regenerate 
upon injury and hypertrophy following exercise.   
Furthermore, rapamycin was shown to cause a loss of 
EC coupling [116] and a reduction in voltage-gated 
Ca2+ release [117] contributing to functional decline.  
Detailed pre-clinical studies in rodents are necessary to 
evaluate any potential negative side effects of TOR 
inhibition on skeletal muscle mass and function. 
 
Therapeutic Interventions: Skeletal muscle-focused 
 
The multiple benefits of CR, not only on sarcopenia but 
also on other age-related diseases, has supported the 
search for and use of CRMs to combat aging and extend 
longevity.  However the current CRMs do not elicit 
such a widespread effect as CR itself and there is 
insufficient evidence that they are able to combat 
sarcopenia.  It is therefore important to entertain the 
hypothesis that management of sarcopenia may consist 
of muscle-specific regimens that may be used in 
conjunction with systemic anti-aging treatments. 
 
Nutrition and Exercise 
Studies have shown that supplementing nutritional 
intake with amino acids spares skeletal muscle from 
sarcopenia.  It causes an increase in mTOR signaling 
believed to result in increased cross-sectional area of 
myofibers and protein synthesis [54, 67].  Furthermore, 
it restored the ratio of type I and 2A fibers and 
increased sarcomere volume [67].  Another contributing 
factor to sarcopenia is a decline in physical activity and 
increased susceptibility to disuse atrophy.  For decades, 
exercise has been recommended to slow down 
sarcopenia. In humans, high-intensity resistance training 
increased muscle strength and cross-sectional area [11, 
12].   Furthermore, it is proposed that the combination 
of increased amino acid intake and daily physical 
activity can additively combat sarcopenia [54].   
Although exercise and nutritional intake are the current 
strategy for managing sarcopenia [118], 
pharmacological approaches may be necessary given 




Other strategies aimed at ameliorating sarcopenia 
directly exploit hormonal imbalances and alterations of 
signaling pathways critical for skeletal muscle tissue 
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drugs, anti-inflammatory drugs, and metabolic agents 
are currently being investigated in regard to a positive 
effect on skeletal muscle mass and function and 
potential use to prevent and/or attenuate sarcopenia.   
We will highlight only a few selected molecules; for an 
extensive review please see [119]. 
 
Testosterone supplementation caused an increase in body 
and muscle weight attenuating the muscle loss associated 
with sarcopenia.  It increased the CSA of both fiber types 
and prevented the age-related fiber-type shift [120].   
Furthermore, it reduced oxidative stress and apoptosis 
[120] while increasing the rate of protein synthesis [121] 
and number of satellite cells [122].  The molecular 
mechanisms underlying the protection mediated by 
testosterone included suppression of myostatin and the 
non-canonical TGF-β pathway via JNK signaling.  In 
addition, testosterone activated Notch1, Akt and G6PDH 
[120].  The effects of testosterone on aged muscle 
function are conflicting.  While most investigators have 
reported an increase in muscle strength [121, 123, 124], 
there is also evidence of no changes [125].  Testosterone 
treatment is controversial due to its side effects including 
increased risk of cardiovascular problems and pedal 
edema.  Furthermore, it is not recommended for patients 
at risk for some medical conditions including sleep 
apnea, urinary tract symptoms and erythrocytosis [119].  
An alternative treatment strategy is the use of synthetic 
androgen modulators that elicit similar results without the 
additional health concerns [126-128]. 
 
The renin-angiotensin pathway has recently been 
implicated in the progression of sarcopenia [129, 130].  
It increases the production of pro-inflammatory 
molecules and promotes degradation of muscle proteins.  
Angiotensin converting enzyme (ACE) inhibitors and 
angiotensin II receptor blockers (ARBs) are two classes 
of drugs used to mediate this pathway and both classes 
have been studied in sarcopenia.  Many clinical trials 
have investigated the use of ACE inhibitors as treatment 
against sarcopenia with non-uniform functional results; 
some reports show improvement while others show no 
change [131-133].  Losartan, an ARB, has shown 
promising pre-clinical results in the treatment of disuse 
atrophy and impaired regeneration in the context of 
sarcopenia through the modulation of the TGF-β and 
Akt/mTOR pathways [60].  However, its effects on the 
progression of sarcopenia in humans remain to be 
elucidated.  One pre-clinical study in rats showed an 
attenuation of muscle strength but did not investigate 
the muscle morphology [134].  
 
IGF-1 has been linked to different aspects of skeletal 
muscle homeostasis including growth, differentiation, 
survival, regeneration and functional profile [47, 135].  
It is documented that systemic levels of IGF-1 decrease 
with age, however, the expression levels of muscle 
intrinsic IGF-1 are not known.  Several investigators 
have shown that skeletal muscle specific over-
expression of IGF-1 is beneficial for sarcopenia.  The 
over-expression of IGF-1 prevents the decline in the 
number of DHPR and RyR1 and restores the functional 
capacity of aged mice [136].  Moreover, localized 
expression of IGF-1 prevented sarcopenia and restored 
the regenerative capacity of aged skeletal muscle [48].  
IGF-1 is beneficial to skeletal muscle; however, its 
sustained expression in cardiac muscle can lead to 
pathological hypertrophy [137, 138].  Therefore, it is 
important to identify molecular targets that increase this 




Sarcopenia is a devastating condition that can lead to 
disability, increased morbidity and mortality.  The age-
related modulation of a variety of signaling pathways 
together with environmental constraints imposed on 
elderly patients accelerate its progression.  The etiology 
of sarcopenia is linked to a variety of pathogenic 
mechanisms and it is therefore challenging to identify 
targeted therapies.  The only currently existing 
management for sarcopenia consists of nutritional 
supplementation and an exercise regimen, albeit with 
only mild beneficial effects.  However, all geriatric 
patients cannot benefit from this treatment. Because 
normal muscle mass and strength are required to 
perform daily activities, it is imperative to identify 
pharmacological compounds that can prevent or slow 
the progression of sarcopenia. 
 
CR has been shown to attenuate various aspects of 
sarcopenia; however, its primary mechanism of action is 
unknown.  The beneficial results have lead to the search 
of CRMs but none of these compounds have been 
demonstrated to combat sarcopenia. Furthermore, it is 
important to emphasize that some of the pathways 
modulated by CRMs are critical for skeletal muscle 
homeostasis casting some doubts as to their potential 
benefit in sarcopenia.  For these reasons, it is imperative 
to identify tissue-specific alterations and responses to 
therapies in aging. 
 
The aging of skeletal muscle is unique from other 
tissues.  Skeletal muscle is a post-mitotic, multi-
nucleated tissue.  Therefore, it is not subjected to 
cellular senescence with age and can undergo 
myonuclear apoptosis.  Furthermore, skeletal muscle 
atrophies with age whereas some tissues hypertrophy. 
Differences also exist in the signaling pathways 
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increased in other tissues but decreased in muscle 
contributing to various age-related pathological 
phenotypes.  These intrinsic differences make finding a 
“one size fits all” therapy for aging nearly impossible.  
Thus far, the only treatment that has shown some 
benefits for various aspects of aging is CR, although 
detailed molecular knowledge about these benefits are 
still lacking.  Once the molecular mechanisms leading 
to beneficial results of CR have been further 
characterized, it will be possible to identify a more 
specific CRM that emulates the effects of CR.  It is 
therefore necessary to combine multiple therapies with 
organ-specific benefits while considering potential 
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